Literature DB >> 15946871

Specific effect of levetiracetam in experimental human pain models.

Thomas P Enggaard1, Niels A Klitgaard, Søren H Sindrup.   

Abstract

BACKGROUND: Levetiracetam is a new antiepileptic drug. There is only limited experience with levetiracetam in clinical neuropathic pain. AIM: To test the analgesic effect of levetiracetam in a human experimental pain model in order to obtain preclinical evidence for its potential effect in neuropathic pain.
METHODS: Sixteen healthy volunteers completed a randomized, double-blind, cross-over trial with a single oral dose of 1500 mg levetiracetam against placebo. Pain tests included pain detection and tolerance to single electrical stimulation and temporal pain summation threshold to repetitive electrical stimulation (3 Hz) of the sural nerve.
RESULTS: Levetiracetam significantly increased the pain tolerance thresholds (p=0.04), and the pain detection thresholds tended to be increased (p=0.06), whereas levetiracetam had no effect on temporal pain summation thresholds (p=0.30).
CONCLUSION: Levetiracetam has an analgesic effect in the electrical sural nerve stimulation pain model, but it did not increase temporal pain summation threshold. Levetiracetam may still be effective in clinical neuropathic pain.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15946871     DOI: 10.1016/j.ejpain.2005.03.011

Source DB:  PubMed          Journal:  Eur J Pain        ISSN: 1090-3801            Impact factor:   3.931


  11 in total

1.  Levetiracetam can be effective in the treatment of restless legs syndrome with periodic limb movements in sleep: report of two cases.

Authors:  G Della Marca; C Vollono; P Mariotti; M Mazza; G F Mennuni; P Tonali; S Mazza
Journal:  J Neurol Neurosurg Psychiatry       Date:  2006-04       Impact factor: 10.154

Review 2.  Translational research in central nervous system drug discovery.

Authors:  Orest Hurko; John L Ryan
Journal:  NeuroRx       Date:  2005-10

Review 3.  Potential of levetiracetam in mood disorders: a preliminary review.

Authors:  Anjana Muralidharan; Zubin Bhagwagar
Journal:  CNS Drugs       Date:  2006       Impact factor: 5.749

4.  SV2 regulates neurotransmitter release via multiple mechanisms.

Authors:  Amy Nowack; Jia Yao; Kenneth L Custer; Sandra M Bajjalieh
Journal:  Am J Physiol Cell Physiol       Date:  2010-08-11       Impact factor: 4.249

Review 5.  Painful and involuntary multiple sclerosis.

Authors:  Francesca Bagnato; Diego Centonze; Simonetta Galgani; Maria Grazia Grasso; Shalom Haggiag; Stefano Strano
Journal:  Expert Opin Pharmacother       Date:  2011-02-17       Impact factor: 3.889

6.  Cotrafficking of SV2 and synaptotagmin at the synapse.

Authors:  Jia Yao; Amy Nowack; Patricia Kensel-Hammes; Richard G Gardner; Sandra M Bajjalieh
Journal:  J Neurosci       Date:  2010-04-21       Impact factor: 6.167

Review 7.  Pain following the repair of an abdominal hernia.

Authors:  Mark Berner Hansen; Kenneth Geving Andersen; Michael Edward Crawford
Journal:  Surg Today       Date:  2009-12-29       Impact factor: 2.549

8.  Levetiracetam reverses synaptic deficits produced by overexpression of SV2A.

Authors:  Amy Nowack; Erik B Malarkey; Jia Yao; Adam Bleckert; Jessica Hill; Sandra M Bajjalieh
Journal:  PLoS One       Date:  2011-12-29       Impact factor: 3.240

9.  SVOP is a nucleotide binding protein.

Authors:  Jia Yao; Sandra M Bajjalieh
Journal:  PLoS One       Date:  2009-04-24       Impact factor: 3.240

Review 10.  Current Status of the New Antiepileptic Drugs in Chronic Pain.

Authors:  Harpreet S Sidhu; Akshay Sadhotra
Journal:  Front Pharmacol       Date:  2016-08-25       Impact factor: 5.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.